Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | GPX4 | P36969 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431410 | 1.00 | BTK (0.39) | BTKPDE4BJAK3EGFRLCK | |
| SCHEMBL20892965 | 1.00 | BTK (0.39) | BTKPDE4BJAK3EGFRLCK | |
| SCHEMBL19958480 | 0.90 | PDE4B (0.40) | BTKPDE4BALDH1A1GPX4 | |
| SCHEMBL20892966 | 0.86 | BTK (0.38) | BTKPDE4BJAK3EGFRLCK | |
| SCHEMBL1630021 | 0.82 | BTK (0.38) | BTKHPGDALDH1A1LMNACPN1 | |
| SCHEMBL26838268 | 0.81 | HPGD (0.31) | HPGD | |
| SCHEMBL20144240 | 0.80 | GPX4 (0.41) | BTKPDE4BALDH1A1CPN1CPB2 | |
| SCHEMBL19353256 | 0.80 | ALDH1A1 (0.54) | BTKHPGDALDH1A1LMNA | |
| SCHEMBL19353266 | 0.80 | ALDH1A1 (0.54) | BTKHPGDALDH1A1LMNA | |
| SCHEMBL10264659 | 0.80 | ALDH1A1 (0.54) | BTKHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2018-07-12 | — | — | US | disclosed |
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| US-9795605-B2 | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | PHARMACYCLICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9556182-B2 | Inhibitors of Bruton's tyrosine kinase | Pharmacylics LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9278100-B2 | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS LLC (US) | 2016-03-08 | — | — | US | disclosed |
| US-20160000792-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC | 2016-01-07 | — | — | US | disclosed |
| US-9181263-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150306106-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-10-29 | — | — | US | disclosed |
| US-20150307500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-10-29 | — | — | US | disclosed |
| US-20120184013-A1 | Inhibitors of BMX non-receptor tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20120178753-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | BLK, DCK, LTK | BTK 14/4885PDE4B 2734/4885JAK3 453/4885 |
| US-20180193345-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | BTK 1/4885PDE4B 2211/4885JAK3 45/4885 |
| US-20150306106-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20160000792-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | BTK 1/4885PDE4B 2211/4885JAK3 45/4885 |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20150307500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | BTK 1/4885PDE4B 2211/4885JAK3 45/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885PDE4B 2328/4885JAK3 253/4885 |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | BTK, ABL1, LYN | BTK 1/4885PDE4B 2211/4885JAK3 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.